Less Ads, More Data, More Tools Register for FREE

Pin to quick picksThg Regulatory News (THG)

Share Price Information for Thg (THG)

Share Price is delayed by 15 minutes
Get Live Data
33.36    0.36 (1.09%)
Bid:
33.16
Ask:
33.42
Spread: 0.26 (0.784%)
Market Cap: £529.37m
THG Live PriceLast checked at - London Stock Exchange

Intraday Thg Share Chart

Transfer to ESCC Category

6 Jan 2025 09:09

RNS Number : 2379S
THG PLC
06 January 2025
Β 

THIS ANNOUNCEMENT DOES NOT CONSTITUTE A PROSPECTUS OR AN EXEMPTION DOCUMENT AND NEITHER THIS ANNOUNCEMENT NOR ANYTHING HEREIN FORMS THE BASIS FOR ANY OFFER TO PURCHASE OR SUBSCRIBE FOR ANY SHARES OR OTHER SECURITIES IN THE COMPANY NOR SHALL IT FORM THE BASIS FOR ANY CONTRACT OR COMMITMENT WHATSOEVER.

6 January 2025

THG PLC

Transfer from the Equity Shares (Transition) CategoryΒ to the Equity Shares (Commercial Companies) Category

THG PLC ("THG" or the "Company") announces the approval by the Financial Conduct Authority (the "FCA") of the transfer of the listing category of the Company's ordinary shares of Β£0.005 each from the equity shares (transition) category of the Official List maintained by the FCA to the equity shares (commercial companies) category of the Official List (the "Transfer").

The Transfer became effective at 8.00 a.m. today, 6 January 2025.

Β 

Enquiries

For further information:

Investor enquiries:

Greg Feehely, SVP Investor Relations

Kate Grimoldby, Director of Investor Relations and Strategic Projects

Investor.Relations@thg.com

Media enquiries:

Sodali & Co - Financial PR adviser

Tel: +44 (0) 20 7250 1446

Victoria Palmer-Moore / Russ Lynch / Sam Austrums

thg@sodali.com

THG PLC

Viki Tahmasebi

Β 

media-enquiries@thg.com

Β 

Barclays Bank PLC (Joint Corporate Broker and Sole Sponsor) ("Barclays")

Tom Johnson

Alastair Blackman

Ben Plant

David Prevezer

Β 

Tel: +44 (0)20 7623 2323​

Β 

IMPORTANT NOTICE:

The contents of this announcement have been prepared by and are the sole responsibility of the Company. The Company is not offering any ordinary shares or other securities in connection with the proposals described in this announcement. This announcement does not constitute or form part of, and should not be construed as, any offer for sale or subscription of, or solicitation of any offer to buy or subscribe for, any securities in the Company or securities in any other entity, in any jurisdiction, or the solicitation of any votes attaching to any securities, nor shall it, or any part of it, or the fact of its distribution, form the basis of, or be relied on in connection with, any contract or investment decision whatsoever, in any jurisdiction. This announcement does not constitute a recommendation regarding any securities.

Subject to the Company's regulatory obligations, including under the UK Listing Rules, the Disclosure Guidance and Transparency Rules, the UK Market Abuse Regulation and the Financial Services and Markets Act 2000 ("FSMA"), neither the Company nor Barclays Bank PLC ("Barclays") undertakes any obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise. None of the statements made in this announcement in any way obviates the requirements of the Company to comply with its regulatory obligations.

Barclays, which is authorised by the Prudential Regulation Authority ("PRA") and regulated by the FCA and the PRA in the United Kingdom, is acting for the Company and for no one else in connection with the Transfer and will not be responsible to any person other than the Company for providing the protections afforded to clients of Barclays, nor for providing advice in relation to the Transfer, the content of this announcement or any matter referred to in this announcement. Apart from the responsibilities and liabilities, if any, which may be imposed on Barclays by the FSMA or the regulatory regime established thereunder, none of Barclays nor any of its subsidiaries, branches or affiliates owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person in connection with this announcement, any statement contained herein or otherwise, nor makes any representation or warranty, express or implied, in relation to, the contents of this announcement, including its accuracy, completeness or verification or for any other statement purported to be made by the Company, or on behalf of the Company, orΒ Barclays, or on behalf of Barclays in connection with the Company or the Transfer. BarclaysΒ and its subsidiaries, branches and affiliatesΒ accordingly disclaim to the fullest extent permitted by law all and any responsibility or liability to any person, whether arising in tort, contract or otherwise (save as referred to above) which they might otherwise have in respect of this announcement or any such statement.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
MSCPKABKCBKKODK
Date   Source Headline
22nd May 20267:00 amRNSNotice of AGM
21st Apr 20267:00 amRNSTrading Statement
20th Apr 20264:45 pmRNSNotice of Q1 Trading Update
8th Apr 20267:00 amRNSAnnual Report & Accounts 2025
26th Mar 20267:00 amRNSPreliminary FY 2025 results
25th Mar 20264:54 pmRNSNotice of Results
24th Feb 20267:45 amRNSPDMR/PCA Shareholding & TR-1 Notification
12th Feb 20267:00 amRNS-RMyprotein licensing partnership with Greencore
2nd Feb 20267:00 amRNSTotal Voting Rights
27th Jan 20263:49 pmRNSTR-1: Notification of major holdings
27th Jan 20263:45 pmRNSTR-1: Notification of Major Holdings
23rd Jan 20262:52 pmRNSTR-1: Notification of Major Holdings
22nd Jan 20263:00 pmRNSApplication for Listing and Total Voting Rights
16th Jan 20267:00 amRNSChange to Board Committee Membership
13th Jan 20267:00 amRNSQ4 2025 Trading Statement
12th Jan 20264:40 pmRNSNotice of Results
2nd Jan 20267:00 amRNSTotal Voting Rights
2nd Jan 20267:00 amRNSTotal Voting Rights
19th Dec 20252:20 pmRNSTR-1: Notification of Major Holdings
19th Dec 20252:20 pmRNSTR-1: Notification of Major Holdings
16th Dec 20255:50 pmRNSTR-1: Notification of Major Holdings
9th Dec 20254:35 pmRNSTR-1: Notification of Major Holdings
9th Dec 202510:55 amRNSTR-1: Notification of Major Holdings
9th Dec 20259:15 amRNSPDMR/PCA Shareholding & TR-1 Notification
5th Dec 202510:15 amRNSDirector Declaration
5th Dec 202510:05 amRNSAdmission of Convertible Loan Shares and TVR
26th Nov 20259:45 amRNSPDMR/PCA Shareholdings
17th Nov 20257:00 amRNS-RMyprotein joins forces with Mars
3rd Nov 20257:00 amRNSBlock listing Interim Review
28th Oct 202511:14 amRNSDirector Declaration
14th Oct 20257:00 amRNSQ3 2025 Trading Statement
10th Oct 20257:00 amRNSNotice of Trading Update
19th Sep 20256:00 pmRNSOcean Wilsons
11th Sep 20257:00 amRNSInterim results for half-year ended 30 June 2025
10th Sep 20254:45 pmRNSNotice of Interim Results
5th Sep 20257:00 amRNSNotification under UKLR 6.4.9R(2)
6th Aug 20257:42 amRNSDisposal, H1 trading and Nutrition update - Amend
6th Aug 20257:00 amRNSDisposal, H1 trading and Nutrition update
9th Jul 20252:24 pmRNSChanges to Directors’ Responsibilities
25th Jun 20252:38 pmRNSResult of AGM
25th Jun 20257:00 amRNSAGM Trading Statement
5th Jun 20253:56 pmRNSTR-1: Notification of Major Holdings
23rd May 20257:00 amRNSNotice of AGM
1st May 20257:00 amRNSBlock Listing Six Monthly Return
30th Apr 20257:00 amRNSAnnual Report & Accounts 2024
29th Apr 20257:00 amRNSFY 2024 results and Q1 trading statement
23rd Apr 20257:00 amRNSResponse to media speculation
16th Apr 20254:45 pmRNSTR-1: Notification of Major Holdings
4th Apr 202510:30 amRNSTR-1: Notification of Major Holdings
4th Apr 20257:00 amRNSCompletion of debt refinancing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.